Datapoint: Novo Working on New Weight Loss Pill

A weight loss pill could be Novo Nordisk’s next blockbuster, CEO Lars Fruergaard Jørgensen told CNBC. While the pill is still years away from approval, a midstage trial is planned for the second half of this year, and results are expected in 2026. Novo’s head of development told Reuters that the company expects to launch the drug, amycretin, sometime in the 2020s. Oral administration could be a major coup for Novo in the weight loss category: GLP-1s, currently the best drugs in the space, are injectables, which poses adherence and market access challenges compared to oral administration. Novo’s GLP-1 approved for weight loss, Wegovy, currently holds covered or better status for 53% of all insured lives, while Lilly’s new Zepbound stands at 31%.

SOURCE: MMIT Analytics, as of 3/20/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 11

Datapoint: Amylyx Pulls ALS Drug Off the Market

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 10

Datapoint: FDA Grants J&J’s Carvykti Earlier, Expanded Use in Multiple Myeloma

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 9

Datapoint: GA Medicaid Expansion Could Bring Coverage to 300,000 People

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today